Palatin Technologies Inc. (PTN)

[oleskool56]

IMO Palatin is looking damn good right now and they already have global rights to bremelanotide for FSD.

The FDA approved Addyi (flibanserin)by Sprout Pharmaceuticals to treat acquired, generalized hypoactive sexual desire disorder (HSDD). But Addyi has serious side effects like can cause severe low blood pressure (hypotension) and loss of consciousness (syncope). These risks are increased and more severe when patients drink alcohol or take Addyi with certain medicines (known as moderate or strong CYP3A4 inhibitors. Palatins Bemelanotide has none of these side effects so once top line data is released and a partnership announced the approval by FDA should be quick.